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Background: Propofol and remifentanil are usually co-administered and have shown synergistic effect for 
anesthesia. However, the synergistic effect of the two drugs on hypnosis measured by bispectral index (BIS) was 
controversial in previous studies. The aim of this study was to identify the interaction of propofol and remifentanil on 
BIS and the optimal dose combinations for hypnosis under 66% N2O during surgery. 
Methods: Patients (age 55-75 and American Society of Anesthesiologists [ASA] 1-2) undergoing gastrectomy were 
enrolled in this study. Propofol and remifentanil were co-administered incrementally at 1 : 1 potent ratio (the P1R1 
group), at 1 : 2 potent ratio (the P1R2 group), or at 2 : 1 potent ratio (the P2R1 group) using effect site target-controlled 
infusion and BIS was measured. 66% N2O was concomitantly administered to all groups. The dose-effect curves, the 
90% effective dose (EC90) for adequate hypnosis (BIS 40), isobolograms and combination index were obtained by 
Calcusyn program (Biosoft) to reveal the interaction of propofol and remifentanil. 
Results: The P2R1 group showed synergistic action on BIS. However, the other groups needed larger amount of each 
drug than the doses of additive action. The EC90 of the P2R1 group was propofol, 3.34 μg/ml and remifentanil, 2.41 
ng/ml under 66% of N2O. 
Conclusions: Propofol dominant co-administration is needed for dose reduction in BIS guided hypnosis. (Korean J 
Anesthesiol 2010; 59: 371-376)
Key Words:  Bispectral index, Isobologram, Propofol, Remifentanil, Synergies.
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Introduction
    Propofol and remifentanil are commonly co-administered in 
intravenous anesthesia and have shown a synergistic effect [1,2]. 
However, reports on hypnotic interaction between propofol and 
remifentanil measured by bispectral index (BIS) have been a 
few and contradictory [3-7]. 
    The combination index (CI), dose-effect curve and 
isobologram have been used in many biomedical studies to 
evaluate drug interactions and to determine the optimal doses 
of combined injection [8-10]. However, there have been few 
studies employing these parameters to analyze the interactions 
of propofol and remifentanil. 
    Therefore, in this study, we determined the interaction of the 
two drugs on BIS and the best hypnotic dose combinations 
using dose-effect curve, isobologram, and CI on patients 
undergoing a gastrectomy.
Materials and Methods 
    This study was approved by the hospital ethics committee 
and informed consent was obtained from the patients. Patients 
undergoing an open gastrectomy were randomly assigned by 
sealed envelope technique into the propofol : remifentanil 1 : 1 
potent ratio (P1R1) group (n = 20), the propofol : remifentanil 
1 : 2 potent ratio (P1R2) group (n = 20) and the propofol : 
remifentanil 2 : 1 potent ratio (P2R1) group (n = 20). The 
inclusion criteria were American Society of Anesthesiologists 
(ASA) 1 or 2 patients between the ages of 55 and 75. The 
exclusion criteria were patients with severe cardiovascular, 
renal, hepatic, or neuropsychiatric diseases, and a history of 
addiction or allergic reactions to opioids and sedatives. Patients 
and an anesthesiologist evaluating the BIS were blinded to 
the group assignment. Modulation of the infusion pump was 
carried out by another anesthesiologist outside of the anesthetic 
field. The demographic profiles and the operation-related data 
were similar in all three groups.
    No patient received premedication. Routine intraoperative 
monitoring and a BIS monitor version 2.1 (A-2000, Aspect 
medical Systems, Natick, MA, USA) were applied. The baseline 
mean blood pressure, heart rate, and BIS were measured when 
the patient was stable before inducing anesthesia. A routine 
anesthetic induction was conducted using lidocaine 40 mg, 
propofol 2.5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane. 
    Study to construct the dose-effect curves was performed after 
the retractor had been applied and during surgical stimuli was 
similarly maintained. Sevoflurane was washed out, while N2O 
2 L/min and O2 1 L/min were started. When the BIS reached 
70, the designated drugs were started according to the groups. 
The drugs were administered by effect site target concentration 
using an Orchestra pump (Orchestra
TM, Fresenius Vial, France). 
No other opioids or sedatives were used during the study.
    In the previous study of Kim and Ahn [11] with the same 
setting with this study, the EC50 of propofol and remifentanil 
single administration was effect site concentration 1.34 μg/ml 
and 1.93 ng/ml, and the EC90 was effect site concentration 4.73 
μg/ml and 12.93 ng/ml, respectively. Based on this EC50, the 
P1R1 group received an equipotent drug infusion; 1/4 × EC50 of 
each drug was co-administered, and the dose was increased to 
1/2 × EC50, EC50, 1.5 × EC50, and 2 × EC50 at 6 minute intervals. 
The P1R2 group received a remifentanil dominant infusion; 
1/4 × EC50 of propofol and 1/2 × EC50 of remifentanil were co-
administered, which were increased to 1/2 × EC50 and EC50, EC50 
and 2 × EC50, 1.5 × EC50 and 3 × EC50 at 6 minute intervals. The 
P2R1 group received a propofol dominant infusion; 1/2 × EC50 of 
propofol and 1/4 × EC50 of remifentanil were co-administered, 
which were increased at 6 min intervals to EC50 and 1/2 × EC50, 2 
× EC50 and EC50, 3 × EC50 and 1.5 × EC50.
    The BIS were measured at the end of every six minutes (6 
minutes : 6 times of the blood-effect site equilibration half-time 
(T1/2keo) of remifentanil [12], 3 times of the [T1/2keo] of propofol 
[13]). The BIS values were calculated by averaging the three 
epochs immediately before the assessment.
    The dose-effect curves, isobologram, and CI of co-admini-
stration groups were constructed using the multiple drug-
effect equation suggested by Chou-Talalay using the Calcusyn 
program (Biosoft, Cambridge, UK) [9]. Targeted BIS was 40 (BIS 
= 40, effect = 1) and effect 0 was the mean baseline BIS (BIS = 
97.3, effect = 0). 
    (fa)1,2/(fu)1,2 = [(D)1/( EC50)1 + (D)2/( EC50)2]
m
Where (D)1, (D)2 : the dose of drug 1 and 2, (EC50)1, (EC50)2: 
the median-effect dose of drug 1 and 2, (fa)1,2: the fraction 
affected by the dose of drug 1 and 2, (fu)1,2: the fraction 
unaffected by the dose of drug 1 and 2, fu = 1 - fa, m: an 
exponent signifying the sigmoidicity (shape) of the dose-
effect curve. 
    CI = (D)1/(Dx)1 + (D)2/(Dx)2 
Where (Dx)1: dose of D1 drug alone that affect a system x%. 
(Dx)2: dose of D2 alone that affect a system x%. (D)1: dose of 
D1 in combination that affect a system x%. (D)2: dose of D2 
in combination that affect a system x%.
    The CI shows the type of interaction of the combined drugs. 
Usually, a CI in the range of 0.9 and 1.1 is considered to be an 
additive action. A CI < 0.9 and CI > 1.1 indicate synergism and 
antagonism, respectively.
    The isobologram is a convenient graphical display, in which 
equipotent pairs of the doses of two drugs are connected by 373 www.ekja.org
Korean J Anesthesiol Kim, et al.
a line, which represents the additive activity between the 
two drugs. Synergism or antagonism was considered to exist 
between the two drugs if the dose of the combined drugs was 
lower or higher than this line, respectively [8]. 
Data analysis
    The primary outcome variable was the difference in the CI 
at EC90 between the three groups. The expected differences in 
means were set at 0.5 with an expected standard deviation of 
0.5. A sample size of 20 in each group was required to achieve 
a power of 80% with an alpha error of 0.05. A z-test with 
Bonferroni's correction was carried out to compare the CI in the 
three groups. The comparisons of the effect site concentrations 
between the co-administration groups were performed by One 
way analysis of variance or Kruskal-Willis one way analysis of 
variance on ranks according to the normality of the data. A P 
value < 0.05 was considered significant.
Results
    No differences in demographic data were evident among the 
three groups (Table 1).
    Mean blood pressure and heart rate were lower in the P1R2 
group compared to the other groups (Fig. 1).
    Each effect site concentration and the corresponding BIS in 
the three groups were shown in the Table 2. 
    In our study, synergism is defined better efficacy than a 
simple additive action shown in isobologram and CI < 0.9. In 
this regard, only the P2R1 group showed synergism. Higher 
effect site concentration of each drug than that in additive 
action was needed in other dose combinations (Table 3, Fig. 
2-4). 
    The EC90 of the P2R1 group was propofol, effect site 
concentration 3.34 μg/ml and remifentanil, effect site 
concentration 2.41 ng/ml under 66% N2O (Table 3, Fig. 3). 
Discussion
    Most previous studies used arbitrary chosen dose combi-
nations of propofol and remifentanil [3-7]. We used propofol 
and remifentanil 1 : 1, 1 : 2, and 2 : 1 ratio combinations based on 
Fig. 1. Hemodynamic changes. *P < 0.05 compared to 15, 30, 45, 60 
minutes in the P1R2 group. 
†P < 0.05 between the P1R2 and P2R1 
group. P1R2: propofol : remifentanil 1 : 2 potency, P2R1: propofol : 
remifentanil 2 : 1 potency.
Table 1. Demographic Data 
Group P1R1 Group P1R2 Group P2R1
Age (yr)
Weight (kg)
Height (cm)
Sex (M/F)
Duration of 
  anesthesia (min)
Duration of 
  operation (min)
63.1 ± 6.0
63.9 ± 10.6
163.7 ± 6.9
16/4
169.5 ± 25.6
144.1 ± 21.9
65.9 ± 6.1
63.6 ± 9.3
162.8 ± 7.4
16/4
165.6 ± 32.2
138.5 ± 26.3
65.1 ± 5.4
62.4 ± 11.9
162.0 ± 8.8
16/4
192.2 ± 52.7
164.5 ± 47.3
Values are mean SD or number of patients. There were no differences 
between the groups. P1R1: propofol : remi  fentanil 1 : 1 potency, P1R2: 
propofol : remifentanil 1 : 2 potency, P2R1: propofol : remifentanil 2 : 
1 potency, M: male, F: female. 
Table 2. The Effect Site Concentration and BIS 
Group P1R1 Group P1R2 Group P2R1
Propofol
EC
(μg/ml)
Remifentanil
EC
(ng/ml)
BIS
Propofol
EC
(μg/ml)
Remifentanil
EC
(ng/ml)
BIS
Propofol
EC
(μg/ml)
Remifentanil
EC
(ng/ml)
BIS
0.3
0.7
1.3
2.0
2.6
0.5
1.0
1.9
2.9
3.9
71.3
68.9
61.3
54.1
46.6
0.3
0.7
1.3
2.0
1.0
1.9
3.9
5.8
71.9
64.3
54.0
47.2
0.7
1.3
2.7
4.0
0.5
1.0
1.9
2.9
68.2
63.7
51.4
40.9
Values are mean. BIS: bispectral index, P1R1: propofol : remifentanil 1 : 1 potency, P1R2: propofol : remifentanil 1 : 2 potency, P2R1: propofol : 
remifentanil 2 : 1 potency, EC: effect site concentration.374 www.ekja.org
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potency to find out whether propofol or remifentanil dominant 
co-administration or the same potent co-administration of 
each drug would be more synergistic. Most previous studies 
also did not include N2O in their studies, however, N2O is 
routinely administered in our institution and in many others 
during propofol and remifentanil anesthesia. To reflect clinical 
practice, we administered 66% N2O simultaneously.
    In this study, the P2R1 group was found to be the most 
effective combination for adequate hypnosis measured by BIS 
and the effect site concentration at EC90 was propofol, 3.34 μg/
ml and remifentanil, 2.41 ng/ml under 66% N2O. 
    In general, most studies on the co-administration of propofol 
and remifentanil have reported synergism. They used the 
clinical responses, such as Observer Assessment of Alertness/
Sedation, autonomic, hemodynamic, or somatic responses to 
various stimuli as a potency measurement of the combined 
drugs [1,2,14,15].
    The studies regarding the interactions of propofol and 
remifentanil on the BIS showed controversial results. Strachan 
and Edwards [3], Koitabashi et al. [4], and Röpcke et al. [5] 
showed the dose-dependent decrease in the BIS or a decrease 
in the propofol requirements to maintain a certain BIS with 
increasing remifentanil concentrations and presented them 
as evidence of synergism. On the contrary to above reports, 
Lysakowski et al. [16] and Guignard et al. [7] found that the 
relationship between propofol effect-site concentration and 
BIS was preserved with or without opioids. Wang et al. [6] 
also found that an infusion of remifentanil did not reduce the 
propofol requirements. 
    In our study, the addition of remifentanil reduced the propofol 
Table 3. EC50, EC90, CI, and DRI 
EC50 EC90
CI
EC50 EC90
Single drug
Group P1R1
Group P1R2
Group P2R1
Propofol
Remifentanil 
Propofol
Remifentanil 
Propofol
Remifentanil 
Propofol
Remifentanil 
1.34 (0.98-1.82)
1.93 (1.52-2.45)
0.50 (0.27-0.93)*
0.72 (0.42-1.27)*
0.42 (0.30-0.59)*
1.21 (0.80-1.85)*
0.89 (0.42-1.85)
0.64 (0.34-1.18)*
4.73 (3.75-6.03)
12.93 (10.93-14.73)
4.16 (3.00-5.40)
5.99 (4.66-8.49)*
2.97 (2.01-3.80)*
8.56 (6.80-10.36)*
3.34 (2.02-4.20)*
2.41 (1.41-3.32)*
0.75 (0.25)
†
0.94 (0.19)
0.99 (0.40)
1.34 (0.66)
1.29 (0.37)
0.89 (0.22)
‡
Values are mean (95% confidence limit) or (SD). EC50: Median effective dose, EC90: 90% effective dose, CI: combination index, P1R1: propofol 
: remifentanil 1 : 1 potency, P1R2: propofol : remifentanil 1 : 2 potency, P2R1: propofol : remifentanil 2 : 1 potency. *P < 0.05 compared to the 
single drug administration. 
†P < 0.05 compared to the P1R2 and P2R1 groups, 
‡P < 0.05 compared to the P1R1 and P1R2 groups.
Fig. 2. The dose-effect curve of propofol of the P1R1, P1R2, and P2R1 
groups. The effect site concentration of propofol in the P1R1, P1R2, 
and P2R1 groups and the hypnotic effect are shown as the X and Y 
axes, respectively. The P2R1 group required the lowest effect site 
concentration of propofol for EC90. P1R1: propofol : remifentanil 1 : 1 
potency, P1R2: propofol : remifentanil 1 : 2 potency, P2R1: propofol : 
remifentanil 2 : 1 potency, EC90: 90% effective dose.
Fig. 3. The dose-effect curve of remifentanil of the P1R1, P1R2, and 
P2R1 groups. The effect site concentration of remifentanil in the 
P1R1, P1R2, and P2R1 groups and the hypnotic effect are shown as 
the X and Y axes, respectively. The P2R1 group required the lowest 
effect site concentration of remifentanil for EC90. P1R1: propofol : 
remifentanil 1 : 1 potency, P1R2: propofol : remifentanil 1 : 2 potency, 
P2R1: propofol : remifentanil 2 : 1 potency, EC90: 90% effective dose.375 www.ekja.org
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requirement and vise versa in all three groups (Table 3, Fig. 2 
and 3). However, synergism should be defined as lower doses 
than the doses of additive action. In this regard, only the P2R1 
group showed synergism at the hypnotic level of BIS. The 
P1R1 and P1R2 groups required larger doses than the doses of 
additive action (Table 3, Fig. 4). 
    No synergistic effect in the P1R1 and P1R2 groups might be 
explained by that opioids have a ceiling effect on EEG. Once 
this ceiling effect has been reached, increasing opioid dosage 
does not further affect the EEG [17]. For another possible 
reason, opioids induce neuroexcitatory phenomena (sharp 
and spike wave activity) on EEG after large doses [18] which 
can be interpreted as high BIS values. Therefore, as a simplified 
EEG measurement, BIS might not reflect the real hypnotic or 
anesthesia in the case of equipotent infusion of propofol and 
remifentanil or remifentanil dominant infusion. And our result 
implies that only propofol dominant co-administration is 
advisable to reduce the amount of each drug during BIS guided 
anesthesia. 
    The limitations of our study include the use of sevoflurane 
before the start of study. We used sevoflurane because we 
assumed that sevoflurane which is more rapidly eliminated 
from the body than intravenous anesthetics would affect less on 
the intravenous concentration of studied drugs. All the groups 
had the same sevoflurane which was almost washed out during 
the study period. The end tidal concentration of sevoflurane 
was 0.10-0.20 vol% when the study started. However, remnant 
sevoflurane might have affected on BIS. For another limitation, 
we administered 66% N2O to all groups to reflect our clinical 
practice. There have been controversies regarding the effect 
of N2O on BIS. Some insisted that N2O up to 70% does not 
affect the BIS [19]. However, addition of N2O to propofol and 
remifentanil co-administration deepened anesthesia and 
prevented movement without affecting BIS [20]. In the contrary, 
others demonstrated significant changes on BIS by N2O [21]. 
Therefore, N2O might have influenced our results, however, with 
keeping the N2O concentrations similar among three groups, 
the focus of our study-interaction of propofol and remifentanil 
on BIS is still considered valid.
    In conclusion, the propofol dominant-infusions are 
recommended for a BIS guided hypnosis and the addition of 
high dose-remifentanil might not result in synergistic dose 
reduction on BIS guided anesthesia.
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